News

Recordati has signed a license agreement with Nycomed for the sales and marketing of silodosin in Italy. Nycomed will also co-market the product along with Recordati in Italy.

Evotec has reported that a further research milestone, leading to payments to Evotec, has been successfully achieved in its drug discovery collaboration with Boehringer Ingelheim. The milestone was

With the reported number of deaths rising to 263 and 60,000 cases of H1N1 virus globally, public health officials are now concerned that influenza could re-emerge as a

Sanofi-aventis has received FDA approval for Sculptra Aesthetic (injectable poly-L-lactic acid), for the correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles. Reportedly, the

Inovio’s SynCon H1N1 influenza DNA vaccines achieved protection against swine origin influenza A/H1N1 viruses in animal studies. The company had previously reported data from an ongoing study in

Sanofi-aventis has reported an increase in net sales by 11.2% to E7.43 billion in the second quarter of 2009, as compared to the net sales of the prior

Valeant has signed a sale and purchase agreement to acquire Tecnofarma for approximately one times sales. Michael Pearson, chairman and CEO of Valeant, said: The acquisition of Tecnofarma

The European Medicines Agency (EMEA) has notified Cell Therapeutics (CTI) that the latter’s pixantrone is eligible to be submitted for a Marketing Authorization Application (MAA). EMEA has also

Access is evaluating strategic options for the commercialization of MuGard in North America. MuGard is an FDA approved treatment for oral mucositis. In connection with the North American